Kelun Highlights First-Line Plans For Merck-Partnered Trop2 ADC

 
• By Dexter Jie Yan
  
first line treatment
1L treatment of EGFR-wild type NSCLC takes center stage in Kelun/Merck's plan for Trop2-targeting ADC • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia